Treatment Access Protocol For Patients Previously Treated With Dacomitinib On A Clinical Trial In Japan
Phase of Trial: Phase II
Latest Information Update: 14 Sep 2017
At a glance
- Drugs Dacomitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Pfizer
- 08 Sep 2017 Status changed from active, no longer recruiting to recruiting.
- 28 Jul 2017 Planned End Date changed from 1 Aug 2017 to 1 May 2019.
- 28 Jul 2017 Planned primary completion date changed from 1 Aug 2017 to 1 May 2019.